Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML
Samuel John, Heyu Chen, Mi Deng, et al.
Molecular Therapy (2018) Vol. 26, Iss. 10, pp. 2487-2495
Open Access | Times Cited: 107

Showing 26-50 of 107 citing articles:

LILRB4-targeting Antibody–Drug Conjugates for the Treatment of Acute Myeloid Leukemia
Yasuaki Anami, Mi Deng, Xun Gui, et al.
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 11, pp. 2330-2339
Open Access | Times Cited: 43
Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
Mi Deng, Heyu Chen, Xiaoye Liu, et al.
Antibody Therapeutics (2021) Vol. 4, Iss. 1, pp. 16-33
Open Access | Times Cited: 34
A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma
Francesco Di Meo, Anjushree Iyer, Keith Akama, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 7, pp. 101110-101110
Open Access | Times Cited: 15
Understanding and Overcoming Immunosuppression Shaped by Cancer Stem Cells
Linheng Li, Roy A. Jensen
Cancer Research (2023) Vol. 83, Iss. 13, pp. 2096-2104
Open Access | Times Cited: 14
Potential therapeutic targets in myeloid cell therapy for overcoming chemoresistance and immune suppression in gastrointestinal tumors
Jiawei Fan, Jianshu Zhu, He Zhu, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 198, pp. 104362-104362
Open Access | Times Cited: 5
CAR-T therapy toxicities: the importance of macrophages in their development and possible targets for their management
Joseph Norton, Patrick J. Stiff
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Hotspots evolution and frontiers of immunotherapy for the treatment of acute myeloid leukemia: A bibliometric analysis
Nana Zhe, Qiang Li, Nanqu Huang, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Machine learning-based bulk RNA analysis reveals a prognostic signature of 13 cell death patterns and potential therapeutic target of SMAD3 in acute myeloid leukemia
Xiebing Bao, Yao Chen, Jie Chang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
LILRB4 specific overexpression in myeloid cells promotes tumor progression and immunosuppression in mouse models
Hongying Wang, Shuhao Ji, Jiashen Zhang, et al.
Biochemical and Biophysical Research Communications (2025) Vol. 755, pp. 151536-151536
Closed Access
CAR T Cells in Lung Cancer: Targeting Tumor-Associated Antigens to Revolutionize Immunotherapy
Sattam Khulaif Alenezi
Pathology - Research and Practice (2025), pp. 155947-155947
Closed Access
Tumor-derived immunoglobulin-like transcript 3 inhibition reshapes the immunosuppressive tumor microenvironment and potentiates programmed cell death ligand 1 blockade immunotherapy in lung adenocarcinoma
Leirong Wang, Qing Li, Yanxin Sun, et al.
Translational Oncology (2025) Vol. 56, pp. 102381-102381
Closed Access
Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy
Calvin D. De Louche, Ali Roghanian
JCI Insight (2022) Vol. 7, Iss. 2
Open Access | Times Cited: 21
Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia
Christopher Schorr, Fabiana Perna
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
LILRB4, an immune checkpoint on myeloid cells
Ting Yang, Yixin Qian, Xiaoting Liang, et al.
Blood Science (2022) Vol. 4, Iss. 2, pp. 49-56
Open Access | Times Cited: 19
LILRB4 as a novel immunotherapeutic target for multiple diseases
Xu Wang, Lanying Li, Dan Liu, et al.
Biochemical Pharmacology (2025), pp. 116762-116762
Closed Access
Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies
Fatemeh Nasiri, Pouya Safarzadeh Kozani, Faeze Salem, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Recent advances of CAR-T cells in acute myeloid leukemia
Huan Deng, Qi Wang, Xiaodong Tong, et al.
Therapeutic Advances in Hematology (2025) Vol. 16
Open Access
LILRB1-directed CAR-T cells for the treatment of hematological malignancies
Katsiaryna Marhelava, Klaudyna Fidyt, Monika Pępek, et al.
Leukemia (2025)
Open Access
Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways
Jan Philipp Bewersdorf, Rory M. Shallis, Amer M. Zeidan
Blood Reviews (2020) Vol. 45, pp. 100709-100709
Closed Access | Times Cited: 32
Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
Ji‐Yoon Noh, Huiyun Seo, Jungwoon Lee, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8000-8000
Open Access | Times Cited: 32
LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Ryan Huang, Xiaoye Liu, Jaehyup Kim, et al.
Cancer Immunology Research (2023) Vol. 12, Iss. 3, pp. 350-362
Open Access | Times Cited: 10
T-cell Redirecting Therapies in Haematological malignancies: Current Developments and Novel Strategies for Improved Targeting
Georgina S.F. Anderson, Michael A. Chapman
Molecular Therapy (2024) Vol. 32, Iss. 9, pp. 2856-2891
Open Access | Times Cited: 3
Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemia
Chanukya K. Colonne, Erik L. Kimble, Cameron J. Turtle
Expert Review of Hematology (2024) Vol. 17, Iss. 11, pp. 797-818
Closed Access | Times Cited: 3
Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled
Jan Philipp Bewersdorf, Maximilian Stahl, Amer M. Zeidan
Expert Review of Anticancer Therapy (2019) Vol. 19, Iss. 5, pp. 393-404
Open Access | Times Cited: 29
LILRB4, from the immune system to the disease target.
Jiachen Liu, Qiwen Wu, Jing Shi, et al.
PubMed (2020) Vol. 12, Iss. 7, pp. 3149-3166
Closed Access | Times Cited: 24

Scroll to top